-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-07-30
Gensci's VEGFR2 mAb NDA Accepted by NMPALearn More
-
2026-07-30
GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical TrialsLearn More
-
2025-12-23
GenSci Partners with Leading AI Company Partex AI to Accelerate Drug Development and Global CommercializationLearn More
-
2025-12-16
GenSci Secures Up to $1.365B in Global ex-China Licensing Deal for GS-098(YB-101) with RTW InvestmentsLearn More
-
2025-12-02
A Leading Force in Innovation:
GenSci Earns Dual Recognition as Global Innovator & 2025 China Pharma Top 100Learn More
-
2025-10-24
GenSci Invites You to Meet Us at CPHI FRANKFURT 2025Learn More
-
2025-10-24
GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMSLearn More
-
2025-10-13
GenSci Advances Women's Health with the Approval of Two Key ProductsLearn More